- Home
- DCOM vs PRAX Comparison
DCOM vs PRAX Comparison
Compare DCOM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- PRAX
- Stock Information
- Founded
- DCOM 1864
- PRAX 2015
- Country
- DCOM United States
- PRAX United States
- Employees
- DCOM N/A
- PRAX N/A
- Industry
- DCOM Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- PRAX Health Care
- Exchange
- DCOM Nasdaq
- PRAX Nasdaq
- Market Cap
- DCOM 1.2B
- PRAX 950.8M
- IPO Year
- DCOM 1996
- PRAX 2020
- Fundamental
- Price
- DCOM $30.81
- PRAX $40.45
- Analyst Decision
- DCOM Strong Buy
- PRAX Strong Buy
- Analyst Count
- DCOM 3
- PRAX 9
- Target Price
- DCOM $36.50
- PRAX $94.44
- AVG Volume (30 Days)
- DCOM 156.6K
- PRAX 406.2K
- Earning Date
- DCOM 10-21-2025
- PRAX 11-05-2025
- Dividend Yield
- DCOM 3.25%
- PRAX N/A
- EPS Growth
- DCOM N/A
- PRAX N/A
- EPS
- DCOM 0.87
- PRAX N/A
- Revenue
- DCOM $314,165,000.00
- PRAX $7,765,000.00
- Revenue This Year
- DCOM $49.66
- PRAX N/A
- Revenue Next Year
- DCOM $16.29
- PRAX $22.22
- P/E Ratio
- DCOM $35.23
- PRAX N/A
- Revenue Growth
- DCOM N/A
- PRAX 338.45
- 52 Week Low
- DCOM $23.25
- PRAX $26.70
- 52 Week High
- DCOM $37.60
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- DCOM 60.08
- PRAX 38.61
- Support Level
- DCOM $30.18
- PRAX $37.19
- Resistance Level
- DCOM $31.07
- PRAX $40.69
- Average True Range (ATR)
- DCOM 0.66
- PRAX 2.41
- MACD
- DCOM -0.03
- PRAX -0.61
- Stochastic Oscillator
- DCOM 62.59
- PRAX 27.77
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.